Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · IEX Real-Time Price · USD
1.990
-0.100 (-4.78%)
At close: Jul 19, 2024, 12:00 AM
2.020
+0.030 (1.51%)
Pre-market: Jul 22, 2024, 9:00 AM EDT
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 285 employees as of December 31, 2023. The number of employees increased by 150 or 111.11% compared to the previous year.
Employees
285
Change (1Y)
150
Growth (1Y)
111.11%
Revenue / Employee
$8,109
Profits / Employee
-$679,235
Market Cap
719.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Weave Communications | 844 |
Sage Therapeutics | 487 |
Wave Life Sciences | 268 |
4D Molecular Therapeutics | 147 |
CARGO Therapeutics | 116 |
Stoke Therapeutics | 110 |
Alumis | 109 |
Arbutus Biopharma | 73 |
LXRX News
- 14 days ago - Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes - GlobeNewsWire
- 4 weeks ago - Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association - GlobeNewsWire
- 5 weeks ago - Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association - GlobeNewsWire
- 7 weeks ago - Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades - Business Wire
- 7 weeks ago - Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 - GlobeNewsWire
- 2 months ago - New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction - GlobeNewsWire
- 2 months ago - Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 - GlobeNewsWire